Ermenegildo Zegna NV
ZGN
DexCom
DXCM
New Fortress Energy
NFE
Workday
WDAY
eBay
EBAY
US Stock MarketDetailed Quotes
VYGR Voyager Therapeutics
- 5.750
- +0.060+1.05%
Close Dec 20 16:00 ET
- 5.750
- 0.0000.00%
Post 16:13 ET
314.10MMarket Cap8.71P/E (TTM)
5.870High5.529Low570.64KVolume5.690Open5.690Pre Close3.27MTurnover1.32%Turnover Ratio1.94P/E (Static)54.63MShares11.72052wk High0.95P/B248.42MFloat Cap5.19052wk Low--Dividend TTM43.20MShs Float31.910Historical High--Div YieldTTM5.99%Amplitude2.460Historical Low5.728Avg Price1Lot Size
Voyager Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -32.86%-27.97M | -3,682.04%-31.58M | -52.44%58.77M | 722.90%77.92M | -94.05%-23.76M | -29.90%-21.05M | 95.48%-835K | 258.93%123.57M | 76.63%-12.51M | -209.37%-12.24M |
| Net income from continuing operations | 65.08%-9.04M | 54.34%-10.14M | -109.13%-11.33M | 385.14%132.33M | 338.70%56.4M | -246.96%-25.9M | -16.35%-22.21M | 681.85%124.04M | 34.82%-46.41M | -513.84%-23.63M |
| Operating gains losses | 910.53%192K | 183.75%227K | 34.09%59K | -52.79%178K | --35K | --19K | --80K | --44K | --377K | ---- |
| Depreciation and amortization | 19.79%1.13M | 28.18%1.39M | 11.26%1.2M | -28.27%4.44M | 60.07%1.34M | -29.53%945K | -9.80%1.09M | -61.77%1.08M | 19.86%6.19M | -43.72%834K |
| Other non cash items | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -0.33%-2.47M | --0 |
| Change In working capital | -868.03%-21.62M | -256.26%-27.41M | 1,723.58%67.2M | -425.13%-66.56M | -1,158.79%-82.78M | 107.54%2.82M | 2,999.67%17.54M | -108.18%-4.14M | 521.46%20.47M | 236.26%7.82M |
| -Change in receivables | -17,024.74%-16.42M | -99.06%206K | 419.23%80.03M | -17,622.95%-83.23M | -904.96%-80.24M | 100.96%97K | 39,860.00%21.98M | -4,866.35%-25.07M | -93.48%475K | 2,202.08%9.97M |
| -Change in prepaid assets | -424.71%-1.12M | 43.44%-1.19M | -156.27%-794K | 103.86%76K | 232.70%418K | 120.75%344K | -1,197.91%-2.1M | 862.70%1.41M | -204.46%-1.97M | -307.24%-315K |
| -Change in payables and accrued expense | -51.45%1.72M | -257.33%-2.22M | -429.70%-3.33M | 795.93%8.05M | 218.81%4.11M | -33.09%3.55M | -343.57%-621K | 135.22%1.01M | 65.95%-1.16M | -683.45%-3.46M |
| -Change in other current assets | 97.41%991K | 184.84%1.39M | 122.17%1.04M | -40.33%1.98M | 69.18%516K | 11.80%502K | -66.94%488K | -56.57%469K | 23.74%3.31M | -10.56%305K |
| -Change in other current liabilities | -122.32%-1.59M | -41.74%-995K | 230.45%891K | 27.77%-2.83M | -48.88%-731K | -44.27%-717K | 56.85%-702K | 47.74%-683K | -14.41%-3.92M | 54.54%-491K |
| -Change in other working capital | -441.27%-5.21M | -1,537.26%-24.61M | -156.84%-10.64M | -60.33%9.41M | -479.07%-6.85M | 96.88%-962K | -168.39%-1.5M | -64.90%18.73M | 1,478.91%23.73M | -38.15%1.81M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -32.86%-27.97M | -3,682.04%-31.58M | -52.44%58.77M | 722.90%77.92M | -94.05%-23.76M | -29.90%-21.05M | 95.48%-835K | 258.93%123.57M | 76.63%-12.51M | -209.37%-12.24M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 140.65%64.35M | -45.74%-35.94M | -762.93%-96.07M | -1,830.00%-141.64M | 90.75%26.83M | -555.92%-158.3M | 31.74%-24.66M | 172.46%14.49M | -111.14%-7.34M | 357.45%14.07M |
| Net PPE purchase and sale | 67.01%-258K | 20.08%-967K | -320.63%-2.14M | -30.71%-3.26M | 19.08%-755K | -181.29%-782K | 2.58%-1.21M | -1,239.47%-509K | -54.82%-2.49M | -168.88%-933K |
| Net investment purchase and sale | 141.02%64.61M | -49.13%-34.98M | -726.16%-93.92M | -2,754.52%-138.39M | 83.92%27.59M | -550.06%-157.52M | 32.78%-23.45M | 175.15%15M | -107.18%-4.85M | 393.14%15M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 140.65%64.35M | -45.74%-35.94M | -762.93%-96.07M | -1,830.00%-141.64M | 90.75%26.83M | -555.92%-158.3M | 31.74%-24.66M | 172.46%14.49M | -111.14%-7.34M | 357.45%14.07M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -95.77%14K | -63.11%571K | 260.49%112.86M | 2,931.08%33.65M | 66.67%460K | 2,106.67%331K | 91.82%1.55M | 260,783.33%31.31M | 81.37%1.11M | 21.59%276K |
| Net common stock issuance | --0 | --0 | 262.39%112.78M | --31.12M | --0 | --0 | --0 | --31.12M | --0 | --0 |
| Proceeds from stock option exercised by employees | -95.77%14K | -63.11%571K | -57.84%78K | 127.39%2.52M | 66.67%460K | 2,106.67%331K | 91.82%1.55M | 1,441.67%185K | 81.37%1.11M | 21.59%276K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -95.77%14K | -63.11%571K | 260.49%112.86M | 2,931.08%33.65M | 66.67%460K | 2,106.67%331K | 91.82%1.55M | 260,783.33%31.31M | 81.37%1.11M | 21.59%276K |
| Net cash flow | ||||||||||
| Beginning cash position | -67.87%79M | -45.91%145.95M | -29.94%70.4M | -15.72%100.47M | -32.03%66.86M | 207.96%245.89M | 101.89%269.84M | -15.72%100.47M | 12.23%119.21M | -13.14%98.38M |
| Current changes in cash | 120.33%36.4M | -179.55%-66.95M | -55.39%75.56M | -60.52%-30.08M | 68.32%3.53M | -1,066.08%-179.02M | 55.49%-23.95M | 1,072.87%169.36M | -244.22%-18.74M | -64.77%2.1M |
| End cash Position | 72.59%115.4M | -67.87%79M | -45.91%145.95M | -29.94%70.4M | -29.94%70.4M | -32.03%66.86M | 207.96%245.89M | 101.89%269.84M | -15.72%100.47M | -15.72%100.47M |
| Free cash flow | -29.28%-28.23M | -1,491.54%-32.55M | -53.98%56.63M | 597.75%74.66M | -86.04%-24.52M | -32.45%-21.83M | 89.63%-2.05M | 257.85%123.06M | 72.79%-15M | -221.47%-13.18M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |